LuminaScanX South Africa Diagnostic Centres (Pty) Ltd is an independent, technology-driven network of outpatient diagnostic imaging centres established to make world-class medical imaging fast, affordable and accessible across South Africa. From four flagship centres in Johannesburg, Pretoria, Cape Town and Durban, the Company will scale through a hub-and-spoke model and mobile imaging units to a national footprint of twenty-five centres, delivering general radiology, ultrasound, CT, MRI, women’s imaging, cardiac imaging and, from Phase II, nuclear medicine, all underpinned by AI-assisted interpretation, teleradiology and a cloud-native patient and referrer platform, LuminaScan Digital™.
The investment case rests on three pillars. First, a large and growing market: South Africa’s medical-imaging market is worth roughly US$454 million and is expanding at mid-single-digit rates, propelled by a rising chronic-disease and cancer burden and by the migration of imaging out of hospitals into lower-cost outpatient settings. Second, a genuine structural constraint the model is built to relieve: South Africa has only about one radiologist per 100,000 people, less than a tenth of Europe’s density, so subspecialist reporting capacity, not equipment, is the binding limit. Teleradiology, AI triage and a centralised reporting hub convert that scarcity into a scalable competitive advantage. Third, a deep private funding pool: roughly nine million medical-scheme beneficiaries, with Discovery Health alone paying more than R89 billion in claims in 2025, underwrite the demand.
|
R320m Initial capital sought |
R710m Year-5 revenue |
R228m Year-5 EBITDA |
25 Centres by Year 5 |
The opportunity
Imaging in South Africa remains fragmented and largely hospital-adjacent, owned by radiology partnerships operating inside private hospital groups, or by regional practices with limited digital reach. No branded, standalone, tech-first outpatient network has consolidated the market at national scale. LuminaScanX targets precisely this whitespace: same-day appointments, reports in two to twelve hours, extended operating hours, cloud image access for patients and referrers, and a materially lower operating cost base than hospital-based imaging.
Financial highlights
The sponsor targets revenue growth from R95 million in Year 1 to R710 million by Year 5, a 7.5× expansion, with EBITDA rising from R18 million to R228 million as utilisation matures and the mix shifts toward higher-value MRI, CT and nuclear-medicine studies. On our independent re-derivation, which loads full depreciation of the equipment base, cash interest and South African taxation, the business records accounting losses in the two ramp years before turning firmly profitable, reaching a re-derived net profit of approximately R93 million by Year 5.
|
R millions |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Revenue |
95 |
185 |
320 |
480 |
710 |
|
EBITDA |
18 |
46 |
92 |
145 |
228 |
|
EBITDA margin |
18.9% |
24.9% |
28.7% |
30.2% |
32.1% |
|
Net profit (re-derived) |
(37.3) |
(23.7) |
3.5 |
40.6 |
93.3 |
|
Net profit (sponsor) |
8 |
24 |
55 |
88 |
142 |
Key findingThe headline case is attractive; the honest case is capital-intensive
Revenue and EBITDA targets are ambitious but achievable for a maturing imaging network. Once full depreciation of the R170 million equipment base and cash interest are applied, Years 1 and 2 are accounting losses of roughly R37 million and R24 million, not the sponsor’s illustrative profits of R8 million and R24 million, and re-derived net profit runs materially below the sponsor’s illustrative line in every year (R93 million versus R142 million by Year 5). The economics remain compelling, a five-year enterprise NPV of about R442 million and a project IRR near 27%, but investors should underwrite the re-derived numbers, and recognise that the early losses are depreciation-heavy and largely non-cash.
Why this business can win
- A scalable answer to a real constraint, teleradiology and AI triage multiply scarce subspecialist reporting capacity across every site and into rural and pan-African markets.
- Structurally lower cost than hospital imaging, with same-day access and 2–12 hour reporting that referrers and schemes value.
- Six diversified revenue streams, walk-in, medical schemes, corporate, hospital outsourcing, teleradiology and AI services, that de-risk any single channel.
- A cloud-native technology spine (LuminaScan Digital™: RIS, PACS, patient app, referrer portal, e-billing) that lowers marginal cost per centre and compounds data advantage.
- A phased rollout that commercialises four cash-generating flagships before funding national expansion, de-risking execution.
The ask
LuminaScanX seeks R320 million of initial capital to establish the platform: R170 million of founding equity alongside a R150 million senior term facility. Scaling to the full twenty-five-centre national network requires a subsequent expansion round, a R100 million Series B equity injection and a R150 million expansion debt facility, lifting peak funded capital to approximately R395 million. A R50 million revolving facility stands available to bridge the 30–60 day medical-scheme settlement cycle.
How this plan goes beyond a template
This document is built to a bankability standard that exceeds off-the-shelf templates such as LivePlan or Upmetrics. Rather than restating the sponsor’s figures, it independently re-derives every line below EBITDA, applies South African tax and financing rules explicitly, integrates the income statement, balance sheet and cash flow so that the balance sheet ties to zero in every year, models the medical-scheme receivable cycle with a dedicated revolving facility, distinguishes the initial platform raise from the peak funding requirement, and stress-tests outcomes across downside and upside scenarios and a one-way sensitivity tornado. Every material divergence between the sponsor’s illustrative figures and the re-derived numbers is disclosed openly. The result is a plan a credit or investment committee can interrogate line by line.